Top Story

Web-based app predicted mutation probability in gliomas

September 26, 2014

A novel interactive Web-based application appears to have utility in accurately identifying IDH1/2 mutation probability in gliomas, according to recent findings.

The program, developed by Craig Horbinski, MD, and colleagues at the University of Kentucky’s Markey Cancer Center, was formulated through research on a cohort of 89 patients with untreated WHO grades II to IV gliomas. Researchers also assessed an external validation cohort of 100 patients with untreated WHO grades II to IV gliomas.

In the Journals

Primary tumor site affected clinical features, outcomes in pediatric neuroblastoma

September 19, 2014
Tumor features and outcomes varied considerably by primary tumor site among children with neuroblastoma, according to study results.Kieuhoa T. Vo, MD, of Benioff…
In the Journals

Sunitinib active in meningioma

August 29, 2014
Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective, multicenter, single-arm phase 2…
FDA News

FDA grants orphan drug status to cannabidiol for glioblastoma multiforme

August 26, 2014
Insys Therapeutics recently announced that the FDA has granted orphan drug designation to a pharmaceutical cannabidiol for the treatment of glioblastoma…
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

figure In the Journals

Web-based app predicted mutation probability in gliomas

September 26, 2014
A novel interactive Web-based application appears to have utility in accurately identifying IDH1/2 mutation probability in gliomas, according to…
In the Journals

Primary tumor site affected clinical features, outcomes in pediatric neuroblastoma

September 19, 2014
Tumor features and outcomes varied considerably by primary tumor site among children with neuroblastoma, according to study results.Kieuhoa T. Vo
In the Journals

Sunitinib active in meningioma

August 29, 2014
Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective…
FDA News

FDA grants orphan drug status to cannabidiol for glioblastoma multiforme

August 26, 2014
Insys Therapeutics recently announced that the FDA has granted orphan drug designation to a pharmaceutical cannabidiol for the treatment of…
Case Challenges

A 54-year-old woman with bilateral hydronephrosis

HemOnc Today, August 25, 2014
Ramya Varadarajan, MD
A 54-year-old black woman presented to her primary care physician after experiencing worsening fatigue and abdominal pain for about 1 month.

Bevacizumab plus lomustine improved outcomes in recurrent glioblastoma

July 30, 2014
The combination of lomustine plus bevacizumab induced higher OS rates than either agent alone, according to results of a randomized, open-label phase…
Institution Notes

Neuroblastoma Research Association presents lifetime achievement award

July 13, 2014
Garrett M. Brodeur, MD, a pediatric oncologist with the Cancer Center at The Children’s Hospital of Philadelphia, received the Advances in…
In the Journals

Risk assessment models predicted VTE risk in high-grade gliomas

July 11, 2014
Researchers used biomarkers to develop two risk assessment models that accurately identified patients with newly diagnosed high-grade gliomas who…
In the Journals

Recurrent VTE linked to certain cancers, leg paresis

July 9, 2014
Specific types of malignancies — including brain, lung and ovarian cancers, as well as myeloproliferative or myelodysplastic disorders —…
Industry News

Glioblastoma vaccine improved OS vs. standard care

July 2, 2014
The addition of heat shock protein-peptide complex-96 vaccine significantly extended OS compared with standard care alone among patients with newly…
More Headlines »